These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35578928)

  • 21. Targeting cholesterol homeostasis in hematopoietic malignancies.
    Brendolan A; Russo V
    Blood; 2022 Jan; 139(2):165-176. PubMed ID: 34610110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.
    Tsimberidou AM; Giles FJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):277-86. PubMed ID: 12113051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
    Jakobsen NA; Vyas P
    Clin Med (Lond); 2018 Apr; 18(Suppl 2):s47-s53. PubMed ID: 29700093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
    Short NJ; Richard-Carpentier G; Kanagal-Shamanna R; Patel KP; Konopleva M; Papageorgiou I; Pemmaraju N; Borthakur G; Ravandi F; DiNardo CD; Kadia TM; Kantarjian H; Lamba JK; Daver N
    Am J Hematol; 2020 Sep; 95(9):E225-E228. PubMed ID: 32356320
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 26. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
    Xie W; Tang G; Wang E; Kim Y; Cloe A; Shen Q; Zhou Y; Garcia-Manero G; Loghavi S; Hu AY; Wang S; Bueso-Ramos CE; Kantarjian HM; Medeiros LJ; Hu S
    Ann Hematol; 2020 Mar; 99(3):487-500. PubMed ID: 32006151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
    Craddock C
    Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
    [No Abstract]   [Full Text] [Related]  

  • 29. Hematological malignancies in Polish population: what are the predictors of outcome in patients admitted to Intensive Care Unit?
    Kalicińska E; Kuszczak B; Dębski J; Szukalski Ł; Wątek M; Strzała J; Rybka J; Czyż J; Lech-Marańda E; Zaucha J; Wróbel T
    Support Care Cancer; 2021 Jan; 29(1):323-330. PubMed ID: 32361829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.
    Foster LH; Lum LG
    Expert Opin Biol Ther; 2019 Jul; 19(7):707-720. PubMed ID: 31081696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemotherapy in elderly patients with hematological malignancies].
    Ohnishi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
    Halpern AB; Othus M; Huebner EM; Scott BL; Hendrie PC; Percival MM; Becker PS; Smith HA; Oehler VG; Orozco JJ; Cassaday RD; Gardner KM; Chen TL; Buckley SA; Orlowski KF; Anwar A; Estey EH; Walter RB
    Haematologica; 2019 Apr; 104(4):e143-e146. PubMed ID: 30409798
    [No Abstract]   [Full Text] [Related]  

  • 33. Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
    Sigal DS; Miller HJ; Schram ED; Saven A
    Blood; 2010 Oct; 116(16):2884-96. PubMed ID: 20634380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
    Pastore F; Levine RL
    Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Precision diagnostics and therapy in hematological malignancies].
    Hellström Lindberg E; Cavelier L; Cammenga J; Andersson PO; Fioretos T; Rosenquist R
    Lakartidningen; 2021 May; 118():. PubMed ID: 33973223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recommendations of the French Society for the Control of Cancers and Leukemias in Children for the treatment of tumor lysis syndrome: results of a pediatric survey].
    Bertrand Y
    Arch Pediatr; 2005 Oct; 12 Spec No 1():13-5. PubMed ID: 17076005
    [No Abstract]   [Full Text] [Related]  

  • 37. Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.
    Sandner AS; Weggel R; Mehraein Y; Schneider S; Hiddemann W; Spiekermann K
    PLoS One; 2019; 14(4):e0215453. PubMed ID: 30998723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Novel conventional therapies in onco-hemathology].
    Baleydier F; Domenech C; Thomas X
    Bull Cancer; 2011 Aug; 98(8):901-13. PubMed ID: 21865110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Grb2 inhibition: a new potential targeted therapy for myeloid malignancies?
    Thomas X; Paubelle E
    Lancet Haematol; 2018 Apr; 5(4):e128-e129. PubMed ID: 29550385
    [No Abstract]   [Full Text] [Related]  

  • 40. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
    Ogasawara K; Newhall K; Maxwell SE; Dell'Aringa J; Komashko V; Kilavuz N; Delarue R; Czuczman M; Sternas L; Rose S; Beach CL; Novick S; Zhou S; Palmisano M; Li Y
    Clin Pharmacokinet; 2020 Feb; 59(2):217-227. PubMed ID: 31332669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.